Yes I agree but let's see how it plays out short term. Even if the FDA do choose to be awkward and the US market timeframe is pushed out by 1 - 2 years they will still be going ahead with 1 x P3 in Europe which is also a very large market with no competitor drug for IIH.
Just depends on what is acceptable to an individual as your investment period in a particular stock. I'm very happy to wait 3 or 4 years - if needs be - in order to net a big return when this firm gets bought out by big pharma. I'd say Andrew Forrest with his $11M (or whatever the figure is) investment seems to be taking a similar approach.
The Trader market in the ASX want their returns in the next 1 - 2 months (or less) so sell out of stocks that don't offer this prospect. Each to their own. Of course if the FDA can be persuaded to allow 1 x P3 for the US then this will re-rate short term you would think.
With the BoD we have running Invex I'm comfortable that medium - long term I will get a very healthy return on my investment. I would however like them to finalise their manufacturing selection.
IXC Price at posting:
66.0¢ Sentiment: Buy Disclosure: Held
